on April 12, 2004
Circulation. 2004
Published online before print April 12, 2004, doi: 10.1161/01.CIR.0000127110.49192.72
Published online before print April 12, 2004, doi: 10.1161/01.CIR.0000127110.49192.72
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© American Heart Association, Inc.
Clinical Investigation and Reports |
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent
The TAXUS-IV Trial
From The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York, NY (G.W.S.); Cleveland Clinic Foundation (S.G.E.); Mid Carolina Cardiology, Charlotte, NC (D.A.C.); St. Vincent’s Hospital, Indianapolis, Ind (J.H.); Elyria Memorial Hospital, Elyria, Ohio (C.O.); WakeMed, Raleigh, NC (J.T.M.); Washington Adventist Hospital, Tacoma Park, MD (M.T.); St. Joseph’s Hospital, Syracuse, NY (R.C.); Sacred Heart Medical Center, Eugene, Ore (P.B.); Florida Hospital, Orlando, Fla (J.G.); Brigham and Women’s Hospital, Boston, Mass (J.J.P.); Boston Scientific Corp, Natick, Mass (M.E.R.).
Correspondence to Gregg W. Stone, MD, The Cardiovascular Research Foundation, 55 E 59th St, 6th Floor, New York, NY 10022. E-mail gstone{at}crf.org
Received February 9, 2004; accepted February 9, 2004.
Background— The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown.
Methods and Results— In the TAXUS-IV trial, 1314 patients with single de novo coronary lesions 10 to 28 mm in length, with reference-vessel diameter 2.5 to 3.75 mm, coverable by a single study stent, were prospectively randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical-appearing bare-metal EXPRESS stent. By actuarial analysis, the TAXUS stent compared with the bare-metal stent reduced the 12-month rates of target-lesion revascularization by 73% (4.4% versus 15.1%, P<0.0001), target-vessel revascularization by 62% (7.1% versus 17.1%, P<0.0001), target-vessel failure by 52% (10.0% versus 19.4%, P<0.0001), and composite major adverse cardiac events by 49% (10.8% versus 20.0%, P<0.0001). The 1-year rates of cardiac death (1.4% versus 1.3%), myocardial infarction (3.5% versus 4.7%), and subacute thrombosis (0.6% versus 0.8%) were similar between the paclitaxel-eluting and control stents, respectively. Between 9 and 12 months, there were significantly fewer myocardial infarctions (0% versus 1.1%, P=0.007), target-vessel revascularizations (2.4% versus 5.8%, P=0.002), and major adverse cardiac events (2.4% versus 6.3%, P=0.0009) in the paclitaxel-eluting stent than in the control stent group, respectively.
Conclusions— The relative efficacy reported at 9 months for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved and continues to increase at 1 year, with no safety concerns apparent.
Key Words: stents • paclitaxel • hyperplasia • restenosis
Related Article:
Circulation 2004 109: 1906-1910.
This article has been cited by other articles:
 |
|
 |
|
  R. A Lookstein, A. D Talenfeld, R. Raju, D. A Vorchheimer, J. W Olin, and M. L Marin Sirolimus-eluting stent placement for refractory renal artery in-stent restenosis: sustained patency and clinical benefit at 24 months Vascular Medicine, November 1, 2009; 14(4): 361 - 364. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Waseda, A. Miyazawa, J. Ako, T. Hasegawa, I. Tsujino, R. Sakurai, P. G. Yock, Y. Honda, D. E. Kandzari, M. B. Leon, et al. Intravascular Ultrasound Results From the ENDEAVOR IV Trial: Randomized Comparison Between Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease J. Am. Coll. Cardiol. Intv., August 1, 2009; 2(8): 779 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 504 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Kim, S. B. King III, K. Kent, M. M. Brooks, K. E. Kip, J. D. Abbott, A. K. Jacobs, C. Rihal, W. A. Hueb, E. Alderman, et al. Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients With Multivessel Coronary Artery Disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) Trial J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Awata, S. Nanto, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, H. Minamiguchi, J.-i. Kotani, et al. Heterogeneous Arterial Healing in Patients Following Paclitaxel-Eluting Stent Implantation: Comparison With Sirolimus-Eluting Stents J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 453 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, Z. Zheng, B. Xu, S. Zhang, W. Li, R. Gao, and S. Hu Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution Circulation, April 21, 2009; 119(15): 2040 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Birim, M. van Gameren, A. J.J.C. Bogers, P. W. Serruys, F. W. Mohr, and A. P. Kappetein Complexity of Coronary Vasculature Predicts Outcome of Surgery for Left Main Disease Ann. Thorac. Surg., April 1, 2009; 87(4): 1097 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Han, Q. Jing, B. Xu, L. Yang, H. Liu, X. Shang, T. Jiang, Z. Li, H. Zhang, H. Li, et al. Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice: 18-Month Clinical and 9-Month Angiographic Outcomes J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Margolis The Excel Stent: A Good DES, But Can We Really Stop Clopidogrel After 6 Months? J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 310 - 311. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. H. Yu, T. W. H. Leung, J. S. Y. Lam, W. W. M. Lam, and L. K. S. Wong Symptomatic Ostial Vertebral Artery Stenosis: Treatment with Drug-eluting Stents--Clinical and Angiographic Results at 1-year Follow-up Radiology, April 1, 2009; 251(1): 224 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Applegate, M. T. Sacrinty, M. A. Kutcher, R. M. Santos, S. K. Gandhi, and W. C. Little 3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Effect of Length and Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes Circ Cardiovasc Interv, February 1, 2009; 2(1): 35 - 42.
|
|
|
|
|
|
G. Yi, Y.-N. Youn, K.-J. Yoo, and Y.-S. Hong Comparison of Off-pump Coronary Artery Bypass Grafting With Percutaneous Coronary Intervention Versus Drug-Eluting Stents for Three-Vessel Coronary Artery Disease Ann. Thorac. Surg., November 1, 2008; 86(5): 1438 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, Z. Zhou, F. S. Resnic, and S.-L. T. Normand Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts Circulation, October 28, 2008; 118(18): 1817 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al. Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study Circ Cardiovasc Interv, August 1, 2008; 1(1): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, P. S. Teirstein, L. Satler, M. H. Sketch Jr, J. J. Popma, L. Mauri, H. Wang, P. A. Schleckser, S. A. Cohen, and SISR Investigators 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 439 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C. H. Pell, I. R. Starkey, et al. Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland J. Public Health Med., June 1, 2008; 30(2): 186 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Groeneveld, M. A. Matta, A. P. Greenhut, and F. Yang Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2017 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Garg, D. J. Cohen, T. Gaziano, and L. Mauri Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1844 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Hannan, M. Racz, D. R. Holmes, G. Walford, S. Sharma, S. Katz, R. H. Jones, and S. B. King III Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents Circulation, April 22, 2008; 117(16): 2071 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Hannan, M. Racz, G. Walford, D. R. Holmes, R. H. Jones, S. Sharma, S. Katz, and S. B. King III Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Applegate, M. T. Sacrinty, M. A. Kutcher, R. M. Santos, S. K. Gandhi, T. T. Baki, and W. C. Little "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 607 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Romagnoli, G. M. Sangiorgi, J. Cosgrave, E. Guillet, and A. Colombo Drug-eluting stenting the case for post-dilation. J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 22 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Hannan, C. Wu, G. Walford, A. T. Culliford, J. P. Gold, C. R. Smith, R. S.D. Higgins, R. E. Carlson, and R. H. Jones Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease N. Engl. J. Med., January 24, 2008; 358(4): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209. [Full Text] [PDF]
|
|
|
|
|
|
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation, January 15, 2008; 117(2): 261 - 295. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]
|
|
|
|
|
|
J. D. Abbott, M. R. Voss, M. Nakamura, H. A. Cohen, F. Selzer, K. E. Kip, H. A. Vlachos, R. L. Wilensky, and D. O. Williams Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2029 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Williams and J. D. Abbott Et Tu, Bare Metal Stent? Circulation, November 20, 2007; 116(21): 2363 - 2365. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Palmerini, F. Barlocco, A. Santarelli, L. Bacchi-Reggiani, C. Savini, E. Baldini, L. Alessi, M. Ruffini, G. Di Credico, G. Piovaccari, et al. A comparison between coronary artery bypass grafting surgery and drug eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >=75 years) Eur. Heart J., November 2, 2007; 28(22): 2714 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Morice, P. W. Serruys, P. Barragan, C. Bode, G.-A. Van Es, H.-P. Stoll, D. Snead, L. Mauri, D. E. Cutlip, and E. Sousa Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents: Five-Year Results of the RAVEL Trial J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kanemitsu, K. Tanaka, J. Tanaka, H. Suzuki, and T. Kinoshita Initial clinical impact of drug eluting stents on coronary artery bypass graft surgery Interactive CardioVascular and Thoracic Surgery, October 1, 2007; 6(5): 632 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Rodriguez, A. O. Maree, J. Mieres, D. Berrocal, L. Grinfeld, C. Fernandez-Pereira, V. Curotto, A. Rodriguez-Granillo, W. O'Neill, and I. F. Palacios Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry Eur. Heart J., September 1, 2007; 28(17): 2118 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Machecourt, N. Danchin, J. M. Lablanche, J. M. Fauvel, J. L. Bonnet, S. Marliere, A. Foote, J. L. Quesada, H. Eltchaninoff, G. Vanzetto, et al. Risk Factors for Stent Thrombosis After Implantation of Sirolimus-Eluting Stents in Diabetic and Nondiabetic Patients: The EVASTENT Matched-Cohort Registry J. Am. Coll. Cardiol., August 7, 2007; 50(6): 501 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ribichini, M. Joner, V. Ferrero, A. V. Finn, J. Crimins, G. Nakazawa, E. Acampado, F. D. Kolodgie, C. Vassanelli, and R. Virmani Effects of Oral Prednisone After Stenting in a Rabbit Model of Established Atherosclerosis J. Am. Coll. Cardiol., July 10, 2007; 50(2): 176 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Weissman, S. G. Ellis, E. Grube, K. D. Dawkins, J. D. Greenberg, T. Mann, L. A. Cannon, P. A. Cambier, S. Fernandez, G. S. Mintz, et al. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials Eur. Heart J., July 1, 2007; 28(13): 1574 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H Wong, S. Wan, and M. J Underwood Myocardial Revascularization: Surgery or Stenting? Asian Cardiovasc Thorac Ann, June 1, 2007; 15(3): 264 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al. Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents JAMA, May 9, 2007; 297(18): 1992 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, W.-h. Hsieh, J. M. Massaro, K. K.L. Ho, R. D'Agostino, and D. E. Cutlip Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents N. Engl. J. Med., March 8, 2007; 356(10): 1020 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes Does Clopidogrel Each Day Keep Stent Thrombosis Away? JAMA, January 10, 2007; 297(2): 209 - 211. [Full Text] [PDF]
|
|
|
|
|
|
E. L. Eisenstein, K. J. Anstrom, D. F. Kong, L. K. Shaw, R. H. Tuttle, D. B. Mark, J. M. Kramer, R. A. Harrington, D. B. Matchar, D. E. Kandzari, et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation JAMA, January 10, 2007; 297(2): 159 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease) Circulation, December 19, 2006; 114(25): 2850 - 2870. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Acosta, E. M. Espana, H. Yamamoto, S. Davis, L. Pinchuk, B. A. Weber, M. Orozco, S. Dubovy, F. Fantes, and J.-M. Parel A Newly Designed Glaucoma Drainage Implant Made of Poly(styrene-b-isobutylene-b-styrene): Biocompatibility and Function in Normal Rabbit Eyes Arch Ophthalmol, December 1, 2006; 124(12): 1742 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Walcher, C. Babiak, P. Poletek, S. Rosenkranz, H. Bach, S. Betz, R. Durst, M. Grub, V. Hombach, J. Strong, et al. C-Peptide Induces Vascular Smooth Muscle Cell Proliferation: Involvement of Src-Kinase, Phosphatidylinositol 3-Kinase, and Extracellular Signal-Regulated Kinase 1/2 Circ. Res., November 24, 2006; 99(11): 1181 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. O. Williams, J. D. Abbott, K. E. Kip, and for the DEScover Investigators Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry Circulation, November 14, 2006; 114(20): 2154 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohtani, K. Egashira, Y. Ihara, K. Nakano, K. Funakoshi, G. Zhao, M. Sata, and K. Sunagawa Angiotensin II Type 1 Receptor Blockade Attenuates In-Stent Restenosis by Inhibiting Inflammation and Progenitor Cells Hypertension, October 1, 2006; 48(4): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J B Dahm, J Ruppert, S Hartmann, D Vogelgesang, A Hummel, and S B Felix Directional atherectomy facilitates the interventional procedure and leads to a low rate of recurrent stenosis in left anterior descending and left circumflex artery ostium stenoses: subgroup analysis of the FLEXI-CUT study Heart, September 1, 2006; 92(9): 1285 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Stahli, G. G. Camici, J. Steffel, A. Akhmedov, K. Shojaati, M. Graber, T. F. Luscher, and F. C. Tanner Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH2 Kinase Activation Circ. Res., July 21, 2006; 99(2): 149 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Cho, T.-Y. Kim, H.-J. Cho, K.-W. Park, S.-Y. Zhang, J.-H. Kim, S.-H. Kim, J.-Y. Hahn, H.-J. Kang, Y.-B. Park, et al. The Effect of Stem Cell Mobilization by Granulocyte-Colony Stimulating Factor on Neointimal Hyperplasia and Endothelial Healing After Vascular Injury With Bare-Metal Versus Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., July 18, 2006; 48(2): 366 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, H. Wang, J. J. Popma, R. E. Kuntz, D. J. Donohoe, J. Schofer, E. Schampaert, B. Meier, M. B. Leon, and J. W. Moses Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents: Pooled Analysis of Five Clinical Trials J. Am. Coll. Cardiol., July 4, 2006; 48(1): 21 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Moses, G. W. Stone, E. Nikolsky, G. S. Mintz, G. Dangas, E. Grube, S. G. Ellis, A. J. Lansky, G. Weisz, M. Fahy, et al. Drug-Eluting Stents in the Treatment of Intermediate Lesions: Pooled Analysis From Four Randomized Trials J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2164 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Blindt, F. Vogt, I. Astafieva, C. Fach, M. Hristov, N. Krott, B. Seitz, A. Kapurniotu, C. Kwok, M. Dewor, et al. A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor Cells J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1786 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Roiron, P Sanchez, A Bouzamondo, P Lechat, and G Montalescot Drug eluting stents: an updated meta-analysis of randomised controlled trials Heart, May 1, 2006; 92(5): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials Heart, May 1, 2006; 92(5): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, M. R. Clark, B. M. Cohen, S. G. Ellis, P. Coleman, C. Hill, C. Shi, et al. Two-Year Outcomes After Sirolimus-Eluting Stent Implantation: Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1350 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Liddicoat, R. De La Torre, K. K.L. Ho, S. Nathan, S. Levitsky, J. Krempin, and F. Sellke Initial Impact of Drug-Eluting Stents on Coronary Artery Bypass Graft Surgery Ann. Thorac. Surg., April 1, 2006; 81(4): 1239 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Urban, A. H. Gershlick, G. Guagliumi, P. Guyon, C. Lotan, J. Schofer, A. Seth, J. E. Sousa, W. Wijns, C. Berge, et al. Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry Circulation, March 21, 2006; 113(11): 1434 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, P. Teirstein, L. Satler, M. Sketch, J. O'Malley, J. J. Popma, R. E. Kuntz, P. J. Fitzgerald, H. Wang, E. Caramanica, et al. Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial JAMA, March 15, 2006; 295(11): 1264 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Williams Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 209 - 220. [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Morice, A. Colombo, B. Meier, P. Serruys, C. Tamburino, G. Guagliumi, E. Sousa, H.-P. Stoll, and for the REALITY Trial Investigators Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial JAMA, February 22, 2006; 295(8): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Beyar, L. Gruberg, D. Deleanu, A. Roguin, Y. Almagor, S. Cohen, G. Kumar, and T. Wenderow Remote-Control Percutaneous Coronary Interventions: Concept, Validation, and First-in-Humans Pilot Clinical Trial J. Am. Coll. Cardiol., January 17, 2006; 47(2): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J. Am. Coll. Cardiol., January 3, 2006; 47(1): 216 - 235. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Nebeker, R. Virmani, C. L. Bennett, J. M. Hoffman, M. H. Samore, J. Alvarez, C. J. Davidson, J. M. McKoy, D. W. Raisch, B. K. Whisenant, et al. Hypersensitivity Cases Associated With Drug-Eluting Coronary Stents: A Review of Available Cases From the Research on Adverse Drug Events and Reports (RADAR) Project J. Am. Coll. Cardiol., January 3, 2006; 47(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Circulation, January 3, 2006; 113(1): 156 - 175. [Full Text] [PDF]
|
|
|
|
|
|
M Thomas Are drug eluting stents really worth the money? Heart, January 1, 2006; 92(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
A Bagust, A D Grayson, N D Palmer, R A Perry, and T Walley Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Heart, January 1, 2006; 92(1): 68 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ramrakha and J. Hill Chapter 15 Major trials in cardiology Oxford Handbook of Cardiology, January 1, 2006; 1(1): med-9780198525974-chapter - med-9780198525974-chapter. [Full Text]
|
|
|
|
|
|
J. A. Alarcon, J. M. Arribas, V. Ruiz, L. Czupryniak, M. Pawlowski, J. Loba, R. F. Bonvini, V. Verin, R. Waksman, R. M. Wolfram, et al. Drug-eluting coronary stents. N. Engl. J. Med., December 1, 2005; 353(22): 2404 - 2408. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Morton, N. D. Arnold, J. Gunn, R. Varcoe, S. E. Francis, S. K. Dower, and D. C. Crossman Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model Cardiovasc Res, December 1, 2005; 68(3): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Abou-Chebl, Q. Bashir, and J. S. Yadav Drug-Eluting Stents for the Treatment of Intracranial Atherosclerosis: Initial Experience and Midterm Angiographic Follow-up Stroke, December 1, 2005; 36(12): e165 - e168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Dawkins, E. Grube, G. Guagliumi, A. P. Banning, K. Zmudka, A. Colombo, L. Thuesen, K. Hauptman, J. Marco, W. Wijns, et al. Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice Circulation, November 22, 2005; 112(21): 3306 - 3313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Stone Update in Cardiology Ann Intern Med, November 15, 2005; 143(10): 737 - 743. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Nawarskas and L. A. Osborn Paclitaxel-eluting stents in coronary artery disease Am. J. Health Syst. Pharm., November 1, 2005; 62(21): 2241 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Moliterno Healing Achilles -- Sirolimus versus Paclitaxel N. Engl. J. Med., August 18, 2005; 353(7): 724 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 J Butany, K Carmichael, S W Leong, and M J Collins Coronary artery stents: identification and evaluation J. Clin. Pathol., August 1, 2005; 58(8): 795 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Brinker, C. J. Davidson, and W. Laskey Preventing in-hospital cardiac and renal complications in high-risk PCI patients Eur. Heart J. Suppl., August 1, 2005; 7(suppl_G): G13 - G24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Henry, M. M. Bonar, P. N. Kearns, H. Cui, M. M. Mutchler, M. V. Martin, A. R. Orsini, H. L. Elford, C. A. Bush, J. L. Zweier, et al. Inhibition of Ribonucleotide Reductase Reduces Neointimal Formation following Balloon Injury J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|